Shortly after Amazon announced its $50 billion investment in OpenAI, AWS invited me on a private tour of the chip lab at the heart of the deal.
Related Posts
Insilico Medicine advances AI drug for IPF to Phase III trials
Insilico Medicine is advancing to Phase III human trials for testing a drug identified by AI targeting idiopathic…
Reid Hoffman weighs in on the ‘tokenmaxxing’ debate
Reid Hoffman says tracking AI token use can gauge adoption, but cautions it should be paired with context…
Why trust is a big question at the Elon Musk-OpenAI trial
A big theme in the trial’s final days was whether OpenAI CEO Sam Altman is trustworthy.